Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2/5 02:14
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN,...